Ladenburg Thalmann initiated coverage on Healthcare Capital with a new price target
$HCCC
Ladenburg Thalmann initiated coverage of Healthcare Capital with a rating of Buy and set a new price target of $18.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/24/2022 | $18.00 | Buy | Ladenburg Thalmann |
25-NSE - Healthcare Capital Corp/DE (0001822935) (Subject)
8-K - Healthcare Capital Corp/DE (0001822935) (Filer)
425 - Healthcare Capital Corp/DE (0001822935) (Subject)
Ladenburg Thalmann initiated coverage of Healthcare Capital with a rating of Buy and set a new price target of $18.00
4 - Healthcare Capital Corp/DE (0001822935) (Issuer)
4 - VISION HYDROGEN Corp (0001676580) (Issuer)
4 - VISION HYDROGEN Corp (0001676580) (Issuer)
JERUSALEM and WILMINGTON, Del., March 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and Healthcare Capital Corp. (NASDAQ:HCCC) ("HCCC"), a special purpose acquisition company, announced today the successful closing of the previously announced business combination (the "Business Combination"). The combined company will continue to be led by Alpha Tau's existing management team. Alpha Tau's ordinary shares and warrants are expected to begin trading on Tuesday, March 8, 2022, on Nasdaq under the ticker symbols "DRTS" and "DRTSW," respectively. The transaction, and the various proposals giving effect ther
NEW YORK and JERUSALEM, ISRAEL , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Healthcare Capital Corp. (NASDAQ:HCCC, HCCCW, and HCCCU))) ("HCCC") and Alpha Tau Medical Ltd. ("Alpha Tau"), an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors, today announced that in its special meeting held on February 18, 2022, HCCC's stockholders voted to approve the previously announced proposed business combination (the "Business Combination") of HCCC and Alpha Tau. Approximately 94.57% of the votes cast at the meeting, representing approximately 65.64% of HCCC's outstanding shares as of the record date, voted
NEW YORK, NY, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Healthcare Capital Corp. (NASDAQ:HCCC, HCCCW, and HCCCU))) ("HCCC") today announced that on February 18, 2022, it convened and then adjourned, without conducting any other business, its special meeting of stockholders (the "Special Meeting"). The Special Meeting has been adjourned until February 18, 2022 at 4:00p.m. Eastern Time (the "Adjournment"). The Special Meeting is being held to approve the business combination (the "Business Combination") with Alpha Tau Medical Ltd. ("Alpha Tau") and related proposals, as described in HCCC's definitive proxy statement filed with the Securities and Exchange Commission ("SEC") on January 14, 2022. The
SC 13G/A - Healthcare Capital Corp/DE (0001822935) (Subject)
SC 13G - Healthcare Capital Corp/DE (0001822935) (Subject)
SC 13G - Healthcare Capital Corp/DE (0001822935) (Subject)